Compare Ascendis Pharma A/S (ASND) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Carlyle Group Inc — how do they compare? Ascendis Pharma A/S trades at $254.01 (market cap $16.67B), while Carlyle Group Inc trades at $48.27 (market cap $17.23B). The key difference: Ascendis Pharma A/S and Carlyle Group Inc are close in size by market cap, and Carlyle Group Inc pays a 2.9% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CG | |
|---|---|---|
Market Cap | $16.67B | $17.23B |
Sector | Health | Financials |
52-Week High | $277.18 | $69.35 |
52-Week Low | $189.74 | $40.52 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 2.9% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
